According to GlaxoSmithKline PLC, a study shows its human papillomavirus vaccine, Cervarix, was effective against the types of HPV that are most likely to cause cervical cancer, but also fought other strains of the disease. A study of 18,644 women between 15 and 25 years, from 14 countries across Europe, Asia-Pacific and Latin and North America, showed significant protection against pre-cancerous lesions not containing the two most common virus types. Those receiving all three doses, the vaccine provided 92.9 percent protection. Results of the study were published in the Lancet.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지